GlobeNewswire

Nasdaq and Celent Publish Global C-Suite Study on Capital Markets Infrastructure Technology

Dela

Report explores C-Suite mindset on R&D, adoption of new business models and technology spe

 

 

NEW YORK and STOCKHOLM, Sweden, June 26, 2018 (GLOBE NEWSWIRE) -- During its biennial Technology of the Future conference in Stockholm, Nasdaq Inc. (Nasdaq:NDAQ), in collaboration with Celent, today revealed the results of a new study of market infrastructure (MI) senior technology and strategy officers that uncovered three important trends: the factors that are driving changes in market infrastructure, how MIs are using technology to support business strategies and how technology spend is evolving.

The report was conducted through in-depth discussions with C-suite executives (including CEOs, COOs, CTOs, CIOs and Heads of Strategy) representing 20 different MI organizations across North America, Europe, Middle East, Asia, and Latin America.

"As market infrastructure operators, our economies are reliant on us to provide a seamless ability for buyers and sellers to come together in a fair environment, find the right price, and trade instantaneously. Technology is the lynchpin of this ecosystem," said Brad Peterson, Chief Technology & Chief Information Officer, Nasdaq. "Our study has shown that nearly all executives interviewed worldwide are looking across borders and embracing the global interconnectedness of our markets. They are tapping technologies such as cloud, APIs, and machine intelligence, while also recognizing the inflexibility and limitations of legacy systems in achieving goals around business expansion and technology scalability. We believe this is a welcomed step in the right direction for the health and longevity of our economies."

"The market infrastructure providers that will stay relevant in the digital age must be agile and flexible players that are not afraid of change," said Josephine de Chazournes, Senior Analyst at Celent and co-author of the report. "They have to be able to reinvent themselves in adjacent businesses, and grasp opportunities even if they are not in their DNA."

"The promised land of digitized capital markets infrastructure does not come without new risks - cyber risk is already a big concern, while money laundering, fraud, and market abuse risks are growing," said Arin Ray, Senior Analyst at Celent and co-author of the report. "It will take industry wide efforts to mitigate the risks."

The key takeaways from the study include:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/89d2c87d-0428-4c8a-94a9-e5d4c278069b

  • Technology is playing an increasingly important role in supporting growth plans. From 10% to 50% of MIs' technology budgets is spent to change the legacy technology and innovating vs. 90% to 50% for the maintenance of systems. The bigger the player the more already amortized are the maintenance costs and thus the split tends to be closer to 50%-50%.

  • Data and analytics are becoming major revenue drivers, and all MIs surveyed are transforming data management practices with plans to offer new data solutions and delivery options such as data-as-a-service. The next goal is to develop advanced analytical tools with AI and machine learning (ML) to create new solutions for investment decision support, risk management and compliance. 
     
  • There is tremendous interest in adopting new technology such as cloud, artificial intelligence (AI), machine learning (ML), and distributed ledger technology (DLT) because they can help develop innovative solutions, new business models, and contribute to significant operational improvements. New solutions are being developed with of one the new technologies (open architecture, cloud enabled, and/or application programming interfaces (APIs)), or at least with provisions to easily incorporate them in the future by 95%of market infrastructures surveyed.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ab9b7f2f-093c-481b-b2cb-3c87c489d597

  • Cloud adoption is becoming mainstream for all participants in our discussion except only one, with 40% already using cloud in some (non-core) functions, and an additional 45% working on pilots. Many large players are finalizing their cloud partners and strategies, and smaller players expect their vendors to deliver the promises of cloud to them. Data privacy and sovereignty issues are a challenge for some players, and clearer regulations and industry standards will be needed for expediting cloud adoption for production data.

  • Artificial intelligence is gaining prominence with leading MIs developing advanced analytical offerings with AI and ML and leveraging the cloud. It is also being used in operations, especially in risk management for surveillance, fraud, and cyber-risk monitoring. Data management and model governance issues can be challenging for some MIs in adopting AI, and many are using AI-enabled solutions from leading international vendors. In the study, 35% of all institutions mentioned they are already using AI, and an equal share working on pilots. On the other hand, robotic process automation (RPA), which is a simpler and more cost-effective technology to automate manual processes, is widely used, and its adoption is growing - 70% of discussion participants mentioned they are already using RPA. 

  • Distributed ledger technology promises to be transformative, especially in post-trade market infrastructure, and almost all players are involved in DLT development projects through partnerships, joint ventures, and industry consortia. Numerous use cases of DLT are emerging in peripheral functions. Because it is still a new and complex technology, not every MI is able to experiment with it individually, but 70% of MIs in the study sample are involved in accelerators, pilots, or industry consortia. 
     
  • Market infrastructure players are increasingly looking for third party solutions because they are cost effective, and compliant with the latest standards and regulations. In core MI functions, there is growing preference to buy and customize third party solutions instead of reinventing the wheel.

  • Cyber-risk is the biggest concern for market infrastructure providers. Indeed all the respondents cited it as such. As MIs engage more with third party providers and fintech startups, everyone in the ecosystem must improve their cyber-security measures, because the system is only as strong as its weakest link. Despite growing recognition of the risks, few are taking concrete steps to address them. It will take industry-wide efforts to overcome these challenges because the new risks will be hard to mitigate by acting in isolation.

To download a copy of the study, please visit here.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $13 trillion.

About Celent

Celent is a research, advisory, and consulting firm focused on financial services technology. We help our Clients make better decisions about technology. Celent publishes research identifying trends and best practices in financial services technology and conducts consulting engagements for financial institutions looking to use technology to enhance existing business processes or launch new business strategies. With a team of internationally-based analysts, Celent is uniquely positioned to offer strategic advice and market insights on a global basis. Celent is a division of the Oliver Wyman Group, which is a wholly owned subsidiary of Marsh & McLennan Companies (NYSE:MMC). 

For Media Inquiries:

Nasdaq
Ryan Wells
ryan.wells@nasdaq.com
Direct: +44 (0) 20 3753 2231
Mobile: +44 (0) 7809 596 390

NDAQG




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nasdaq via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum